272 related articles for article (PubMed ID: 34030872)
41. Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy.
Hung CH; Wang JH; Lu SN; Hu TH; Lee CM; Chen CH
J Viral Hepat; 2017 Jul; 24(7):599-607. PubMed ID: 28130815
[TBL] [Abstract][Full Text] [Related]
42. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.
Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL
Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549
[TBL] [Abstract][Full Text] [Related]
43. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.
Fung J; Cheung KS; Wong DK; Mak LY; To WP; Seto WK; Lai CL; Yuen MF
Hepatology; 2018 Aug; 68(2):462-472. PubMed ID: 29534307
[TBL] [Abstract][Full Text] [Related]
44. Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA.
Kim DH; Choi JW; Seo JH; Cho YS; Won SY; Park BK; Jeon HH; Shin SY; Lee CK
Yonsei Med J; 2017 May; 58(3):552-556. PubMed ID: 28332360
[TBL] [Abstract][Full Text] [Related]
45. A new scheme with infusion of hepatitis B immunoglobulin combined with entecavir for prophylaxis of hepatitis B virus recurrence among liver transplant recipients.
Chen G; Liu H; Hu ZQ; Bai JH; Liu QY; Zhao YP; Gan XM; Wang F; Wang DD; Ma LJ; Li L
Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):901-6. PubMed ID: 26011237
[TBL] [Abstract][Full Text] [Related]
46. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years.
Wong GL; Wong VW; Chan HY; Tse PC; Wong J; Chim AM; Yiu KK; Chu SH; Chan HL
Aliment Pharmacol Ther; 2012 Jun; 35(11):1326-35. PubMed ID: 22506552
[TBL] [Abstract][Full Text] [Related]
47. The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence.
Idilman R; Akyildiz M; Keskin O; Gungor G; Yilmaz TU; Kalkan C; Dayangac M; Cinar K; Balci D; Hazinedaroglu S; Tokat Y
Clin Transplant; 2016 Oct; 30(10):1216-1221. PubMed ID: 27409074
[TBL] [Abstract][Full Text] [Related]
48. Clinical-pathological analysis of hepatitis B virus recurrence after liver transplantation in Chinese patients.
Gao YJ; Zhang M; Jin B; Meng FP; Ma XM; Liu ZW; Su HB; Zhao JM; Li HW
J Gastroenterol Hepatol; 2014 Mar; 29(3):554-60. PubMed ID: 24117714
[TBL] [Abstract][Full Text] [Related]
49. Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis.
Wadhawan M; Gupta S; Goyal N; Taneja S; Kumar A
Liver Transpl; 2013 Sep; 19(9):1030-5. PubMed ID: 23788470
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice.
Ridruejo E; Marciano S; Galdame O; Reggiardo MV; Muñoz AE; Adrover R; Cocozzella D; Fernandez N; Estepo C; Mendizabal M; Romero GA; Levi D; Schroder T; Paz S; Fainboim H; Mandó OG; Gadano AC; Silva MO
Ann Hepatol; 2014; 13(3):327-36. PubMed ID: 24756007
[TBL] [Abstract][Full Text] [Related]
51. Oral Nucleos(t)ide Analogs Alone After Liver Transplantation in Chronic Hepatitis B With Preexisting rt204 Mutation.
Fung J; Wong T; Chok K; Chan A; Sin SL; Cheung TT; Dai WC; Ng K; Ng K; Man K; Seto WK; Lai CL; Yuen MF; Lo CM
Transplantation; 2017 Oct; 101(10):2391-2398. PubMed ID: 28731907
[TBL] [Abstract][Full Text] [Related]
52. Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma.
Urata Y; Kubo S; Takemura S; Uenishi T; Kodai S; Shinkawa H; Sakae M; Kaneda K; Ohata K; Nozawa A; Suehiro S
J Hepatobiliary Pancreat Sci; 2012 Nov; 19(6):685-96. PubMed ID: 22203455
[TBL] [Abstract][Full Text] [Related]
53. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
[TBL] [Abstract][Full Text] [Related]
54. Perioperative antiviral therapy improves the prognosis of HBV DNA-negative patients with HBV-related hepatocellular carcinoma.
Li C; Li ZC; Ma L; Li LQ; Zhong JH; Xiang BD; Gong WF
Expert Rev Gastroenterol Hepatol; 2020 Aug; 14(8):749-756. PubMed ID: 32552297
[TBL] [Abstract][Full Text] [Related]
55. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
[TBL] [Abstract][Full Text] [Related]
56. Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
Choi J; Jo C; Lim YS
Hepatology; 2021 Feb; 73(2):661-673. PubMed ID: 32324905
[TBL] [Abstract][Full Text] [Related]
57. Resistance of ground glass hepatocytes to oral antivirals in chronic hepatitis B patients and implication for the development of hepatocellular carcinoma.
Tsai HW; Lin YJ; Wu HC; Chang TT; Wu IC; Cheng PN; Yen CJ; Chan SH; Huang W; Su IJ
Oncotarget; 2016 May; 7(19):27724-34. PubMed ID: 27027237
[TBL] [Abstract][Full Text] [Related]
58. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine.
Lim YS; Han S; Heo NY; Shim JH; Lee HC; Suh DJ
Gastroenterology; 2014 Jul; 147(1):152-61. PubMed ID: 24583062
[TBL] [Abstract][Full Text] [Related]
59. Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients.
Fernández I; Loinaz C; Hernández O; Abradelo M; Manrique A; Calvo J; Manzano M; García A; Cambra F; Castellano G; Jiménez C
Transpl Infect Dis; 2015 Oct; 17(5):695-701. PubMed ID: 26257166
[TBL] [Abstract][Full Text] [Related]
60. Entecavir Combined With Adefovir Ameliorates Patients With Chronic Hepatitis B Who Fail to Respond to Nucleotide (Acid) Analog Monotherapy.
Li XY; You X; Jie YS; Lin GL; Wu YK; Huang MX; Zhang M; Li ZY; Xie DY; Gao ZL; Chong YT
Am J Ther; 2017 May; 24(3):e250-e258. PubMed ID: 25923228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
